COVID-19 Outcomes in MS Patients in the Middle East
Published on Thu, 22 Feb 2024
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
A study conducted across Oman, Kuwait, and the UAE assessed COVID-19 prevalence, severity, and risk factors in multiple sclerosis (MS) patients. Among 134 cases (3.7% prevalence), 94% had mild illness, 91% recovered fully, and one patient (0.7%) died. Key risk factors for severe outcomes included high EDSS scores, progressive MS, and anti-CD20 therapies like rituximab. Comorbidities also increased risks of non-recovery. Age, sex, and MS duration were not significant predictors. These findings can help optimize treatment and monitoring for MS patients during COVID-19.